The Clinical and Genomic Epidemiology of Rhinovirus in Homeless Shelters-King County, Washington.
COVID-19 pandemic
congregate setting
epidemiology
genomic analysis
homeless shelter
people experiencing homelessness
respiratory pathogen
respiratory viral infection
rhinovirus
Journal
The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675
Informations de publication
Date de publication:
07 10 2022
07 10 2022
Historique:
pubmed:
25
6
2022
medline:
12
10
2022
entrez:
24
6
2022
Statut:
ppublish
Résumé
Rhinovirus (RV) is a common cause of respiratory illness in all people, including those experiencing homelessness. RV epidemiology in homeless shelters is unknown. We analyzed data from a cross-sectional homeless shelter study in King County, Washington, October 2019-May 2021. Shelter residents or guardians aged ≥3 months reporting acute respiratory illness completed questionnaires and submitted nasal swabs. After 1 April 2020, enrollment expanded to residents and staff regardless of symptoms. Samples were tested by multiplex RT-PCR for respiratory viruses. A subset of RV-positive samples was sequenced. There were 1066 RV-positive samples with RV present every month of the study period. RV was the most common virus before and during the coronavirus disease 2019 (COVID-19) pandemic (43% and 77% of virus-positive samples, respectively). Participants from family shelters had the highest prevalence of RV. Among 131 sequenced samples, 33 RV serotypes were identified with each serotype detected for ≤4 months. RV infections persisted through community mitigation measures and were most prevalent in shelters housing families. Sequencing showed a diversity of circulating RV serotypes, each detected over short periods of time. Community-based surveillance in congregate settings is important to characterize respiratory viral infections during and after the COVID-19 pandemic. NCT04141917.
Sections du résumé
BACKGROUND
Rhinovirus (RV) is a common cause of respiratory illness in all people, including those experiencing homelessness. RV epidemiology in homeless shelters is unknown.
METHODS
We analyzed data from a cross-sectional homeless shelter study in King County, Washington, October 2019-May 2021. Shelter residents or guardians aged ≥3 months reporting acute respiratory illness completed questionnaires and submitted nasal swabs. After 1 April 2020, enrollment expanded to residents and staff regardless of symptoms. Samples were tested by multiplex RT-PCR for respiratory viruses. A subset of RV-positive samples was sequenced.
RESULTS
There were 1066 RV-positive samples with RV present every month of the study period. RV was the most common virus before and during the coronavirus disease 2019 (COVID-19) pandemic (43% and 77% of virus-positive samples, respectively). Participants from family shelters had the highest prevalence of RV. Among 131 sequenced samples, 33 RV serotypes were identified with each serotype detected for ≤4 months.
CONCLUSIONS
RV infections persisted through community mitigation measures and were most prevalent in shelters housing families. Sequencing showed a diversity of circulating RV serotypes, each detected over short periods of time. Community-based surveillance in congregate settings is important to characterize respiratory viral infections during and after the COVID-19 pandemic.
CLINICAL TRIALS REGISTRATION
NCT04141917.
Identifiants
pubmed: 35749582
pii: 6617600
doi: 10.1093/infdis/jiac239
pmc: PMC9384451
doi:
Banques de données
ClinicalTrials.gov
['NCT04141917']
Types de publication
Clinical Study
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
S304-S314Subventions
Organisme : NIAID NIH HHS
ID : T32 AI007044
Pays : United States
Organisme : NIH HHS
ID : S10OD028685
Pays : United States
Organisme : CDC HHS
ID : 75D30120C09322 AM002
Pays : United States
Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Déclaration de conflit d'intérêts
Potential conflicts of interest. E. J. C. reports honoraria from Providence Health and Services, Seattle, WA for presentations on COVID-19. S. N. C. reports honoraria from University of California, Berkeley for presentations on COVID-19. P. R. reports honoraria from the Bill and Melinda Gates Foundation for presentations on COVID-19. J A. E. reports consultation for with Sanofi Pasteur, AstraZeneca, and Meissa Vaccines; and has received research funding from AstraZeneca, GlaxoSmithKline, Merck, and Pfizer outside the submitted work. H. Y. C. reports consultation for Ellume, Pfizer, the Bill and Melinda Gates Foundation, Glaxo Smith Kline, and Merck; and has received research funding from Gates Ventures and Sanofi Pasteur, and support and reagents from Ellume and Cepheid outside of the submitted work. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.